Пређи на садржај

Gabapentin

С Википедије, слободне енциклопедије
Gabapentin
Klinički podaci
Prodajno imeAclonium, Neurontin, Novo-Gabapentin
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije5-7 h
IzlučivanjeRenalno
Identifikatori
CAS broj60142-96-3 ДаY
ATC kodN03AX12 (WHO)
PubChemCID 3446
DrugBankDB00996 ДаY
ChemSpider3328 ДаY
ChEMBLCHEMBL940 ДаY
Hemijski podaci
FormulaC9H17NO2
Molarna masa171,237
  • NCC1(CC(O)=O)CCCCC1
  • InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12) ДаY
  • Key:UGJMXCAKCUNAIE-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja162—166 °C (324—331 °F)

Gabapentin je organsko jedinjenje, koje sadrži 9 atoma ugljenika i ima molekulsku masu od 171,237 Da.[1][2][3][4][5][6][7][8][9]

Osobina Vrednost
Broj akceptora vodonika 3
Broj donora vodonika 2
Broj rotacionih veza 3
Particioni koeficijent[10] (ALogP) -1,5
Rastvorljivost[11] (logS, log(mol/L)) -2,0
Polarna površina[12] (PSA, Å2) 63,3
  1. ^ Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S: Efficacy of gabapentin in migraine prophylaxis. Mathew, N. T.; Rapoport, A.; Saper, J.; Magnus, L.; Klapper, J.; Ramadan, N.; Stacey, B.; Tepper, S. (2001 Feb). „Efficacy of gabapentin in migraine prophylaxis”. Headache. 41 (2): 119—28. PMID 11251695. doi:10.1046/j.1526-4610.2001.111006119.x.  Проверите вредност парамет(а)ра за датум: |date= (помоћ). .
  2. ^ Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med. 2004 Mar;5 Suppl 1:S28-47. . Backonja, M. M.; Serra, J. (2004). „Pharmacologic management part 1: Better-studied neuropathic pain diseases”. Pain Medicine (Malden, Mass.). 5 Suppl 1: S28—47. PMID 14996228. doi:10.1111/j.1526-4637.2004.04020.x. 
  3. ^ Choudhuri I, Sarvananthan N, Gottlob I: Survey of management of acquired nystagmus in the United Kingdom. Choudhuri, I.; Sarvananthan, N.; Gottlob, I. (2007 Sep). „Survey of management of acquired nystagmus in the United Kingdom”. Eye. 21 (9): 1194—7. PMID 16732211. doi:10.1038/sj.eye.6702434.  Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2006 May 26. .
  4. ^ Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000 Sep;2(3 Pt 2):249-55. . Pande, A. C.; Crockatt, J. G.; Janney, C. A.; Werth, J. L.; Tsaroucha, G. (2000). „Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group”. Bipolar Disorders. 2 (3 Pt 2): 249—255. PMID 11249802. doi:10.1034/j.1399-5618.2000.20305.x. 
  5. ^ Su TZ, Feng MR, Weber ML. (2005 Jun). „Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells.”. J Pharmacol Exp Ther. 313 (3): 1406—15. PMID 15769862. doi:10.1124/jpet.104.082255.  Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2005 Mar 15. .
  6. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  7. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  8. ^ Khademi S, Ghaffarpasand F, Heiran HR, Asefi A (2010). „Effects of preoperative gabapentin on postoperative nausea and vomiting after open cholecystectomy: A prospective randomized double-blind placebo-controlled study”. Med Princ Pract. 19: 57—60. doi:10.1159/000252836. 
  9. ^ Bashir F, Bhat KM, Qazi S, Hashia AM (2009). „A randomized, double blind, placebo controlled study evaluating preventive role of gabapentin for PONV in patients undergoing laparascopic cholecystectomy”. JK Sci. 11: 190—3. 
  10. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  11. ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  12. ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).